BioMarin Pharmaceutical Inc. BMRN reported earnings of 3 cents per share in the first quarter of 2017 (including stock-based compensation expense), significantly better than the year-ago loss of 36 cents and the Zacks Consensus …
While Editas is still in the pre-clinical stage -- and is thus an extremely speculative stock -- the company has announced a ... The Motley Fool recommends BioMarin Pharmaceutical, Editas Medicine, and Pacific Biosciences of California.
So what:This isn't the first time rumors of an offer from the big pharma have boosted shares of BioMarin. About three years ago, Roche's CEO, Severin Schwan, was quick to dispel the notion, but this time around he hasn't had much to say. …
Our proven model does not conclusively show that BioMarin is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to …
Yahoo!4mon
... play on BioMarin Pharmaceutical (BMRN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Mar 16, 2018 $90 covered call for a net debit in the $86.18 area. That is also the break-even stock price for the covered …
Piper Jaffray & Co. initiates coverage on BioMarin Pharmaceutical (Nasdaq: BMRN) with a Neutral. Price target …
About BioMarin Pharmaceutical, Inc. BioMarin is a global biotechnology ... As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities …
10 stocks we like better than BioMarin Pharmaceutical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the …